Clinical Use of Intravenous Iron: Administration, Efficacy, and Safety

被引:213
作者
Auerbach, Michael [1 ]
Ballard, Harold [2 ]
机构
[1] Georgetown Univ, Sch Med, Baltimore, MD 21237 USA
[2] NYU, Sch Med, New York, NY USA
关键词
FERRIC GLUCONATE COMPLEX; RECOMBINANT-HUMAN-ERYTHROPOIETIN; ADVERSE DRUG EVENTS; STAGE RENAL-DISEASE; TOTAL-DOSE INFUSION; HEMODIALYSIS-PATIENTS; ORAL IRON; PARENTERAL IRON; ANEMIC PATIENTS; IV IRON;
D O I
10.1182/asheducation-2010.1.338
中图分类号
G40 [教育学];
学科分类号
040101 ; 120403 ;
摘要
This section reviews the history, pharmacology, administration, efficacy, and toxicity of intravenous iron. Intravenous iron offers advantages over oral iron for the treatment of iron deficiency anemia across a wide range of disease states associated with absolute and functional iron deficiency. However, there remain concerns about the acute safety profiles of the available preparations and the potential for long-term toxicity with their repeated administration. Seven intravenous iron formulations are available. Confusion concerning the relative toxicities of the different formulations abounds. The similarities and differences are discussed. Iron repletion has been associated with adverse outcomes in infections. The relationship, if any, between intravenous iron administration and infections is reviewed. The potential advantages of total dose infusion (TDI), complete repletion in a single setting, are highlighted. A new paradigm for iron replacement therapy in iron deficiency anemia is presented.
引用
收藏
页码:338 / 347
页数:10
相关论文
共 72 条
[1]   Erythropoietin for end-stage renal disease [J].
Adamson, JW ;
Eschbach, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :625-627
[2]   Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease [J].
Agarwal, R ;
Vasavada, N ;
Sachs, NG ;
Chase, S .
KIDNEY INTERNATIONAL, 2004, 65 (06) :2279-2289
[3]   Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. [J].
Anker, Stefan D. ;
Comin Colet, Josep ;
Filippatos, Gerasimos ;
Willenheimer, Ronnie ;
Dickstein, Kenneth ;
Drexler, Helmut ;
Luescher, Thomas F. ;
Bart, Boris ;
Banasiak, Waldemar ;
Niegowska, Joanna ;
Kirwan, Bridget-Anne ;
Mori, Claudio ;
Rothe, Barbara von Eisenhart ;
Pocock, Stuart J. ;
Poole-Wilson, Philip A. ;
Ponikowski, Piotr .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (25) :2436-2448
[4]  
[Anonymous], AM J GASTROENTEROL
[5]   Iron sucrose in hemodialysis patients: Safety of replacement and maintenance regimens [J].
Aronoff, GR ;
Bennett, WM ;
Blumenthal, S ;
Charytan, C ;
Pennell, JP ;
Reed, J ;
Rothstein, M ;
Strom, J ;
Wolfe, A ;
Van Wyck, D ;
Yee, J .
KIDNEY INTERNATIONAL, 2004, 66 (03) :1193-1198
[6]   Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial [J].
Auerbach, M ;
Ballard, H ;
Trout, JR ;
McIlwain, M ;
Ackerman, A ;
Bahrain, H ;
Balan, S ;
Barker, L ;
Rana, J .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1301-1307
[7]   A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients [J].
Auerbach, M ;
Winchester, J ;
Wahab, A ;
Richards, K ;
McGinley, M ;
Hall, F ;
Anderson, J ;
Briefel, G .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (01) :81-86
[8]   Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: A double blind randomized trial [J].
Auerbach, M ;
Chaudhry, M ;
Goldman, H ;
Ballard, H .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1998, 131 (03) :257-260
[9]   The role of intravenous iron in anemia management and transfusion avoidance [J].
Auerbach, Michael ;
Goodnough, Lawrence Tim ;
Picard, Dan ;
Maniatis, Alice .
TRANSFUSION, 2008, 48 (05) :988-1000
[10]   Intravenous iron: From anathema to standard of care [J].
Auerbach, Michael ;
Coyne, Dan ;
Ballard, Harold .
AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (07) :580-588